Moffitt logo

Clinical Trials Search

Clinical Trial 19662

Cancer Type: Gynecological Tumor
Interventions:Atezolizumab (Tecentriq)

Study Type: Treatment
Phase of Study: Phase II
Investigators:

  • Kamran Ahmed

Call 813-745-6100
or 1-800-679-0775
Overview

Study Title

Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer

Summary

Objective

Primary Objective:To evaluate the ORR by Immune-Modified Response Evaluation Criteria in Solid Tumors (irRECIST) criteria of SBRT and atezolizumab in the management of recurrent/persistent/metastatic cervical cancer. Secondary Objective: To assess safety by Common Terminology Criteria for Adverse Events (CTCAE) v5 following SBRT and atezolizumab in the management of recurrent/persistent/metastatic cervical cancer. To determine local control rates of irradiated lesions following SBRT and atezolizumab in the management of recurrent/persistent/metastatic cervical cancer. To determine progression-free survival (PFS) following combined modality management with SBRT and atezolizumab in the management of recurrent/persistent/metastatic cervical cancer. To determine overall survival (OS) following combined modality management with SBRT and atezolizumab in the management of recurrent/persistent/metastatic cervical cancer. To evaluate whether PD-L1 expression is a predictive biomarker for ORR in the management of recurrent/persistent/metastatic cervical cancer.

Inclusion Criteria

  • At least 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) ≤ 2 or Karnofsky Performance Status of ≥ 60
  • Participants must have recurrent, persistent, or metastatic cervical cancer, including squamous cell, adenocarcinoma, and adenosquamous histologies
  • Measurable disease per irRECIST: Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation. Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm (≥1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam.
  • Must have at least 2 distinct lesions as documented by imaging studies within 4 weeks prior to randomization
  • Consent to biopsy of metastatic site or consent to retrieval of archival tissue

  • Exclusion Criteria

  • Patients with known brain metastasis
  • Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions: Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study, Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
  • History of prior malignancy within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of > 90%), such as but not limited to, non-melanoma skin carcinoma, ductal carcinoma in situ, or stage I endometrioid uterine cancer, and others at the discretion of the Principal Investigator (PI)
  • Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF)-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study, with the following exceptions: Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy), Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency